IL136511A0 - Genetically engineered mhc molecules - Google Patents

Genetically engineered mhc molecules

Info

Publication number
IL136511A0
IL136511A0 IL13651100A IL13651100A IL136511A0 IL 136511 A0 IL136511 A0 IL 136511A0 IL 13651100 A IL13651100 A IL 13651100A IL 13651100 A IL13651100 A IL 13651100A IL 136511 A0 IL136511 A0 IL 136511A0
Authority
IL
Israel
Prior art keywords
component
cells
polypeptide
class
zeta
Prior art date
Application number
IL13651100A
Other languages
English (en)
Original Assignee
Gavish Galilee Bio Appl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gavish Galilee Bio Appl Ltd filed Critical Gavish Galilee Bio Appl Ltd
Priority to IL13651100A priority Critical patent/IL136511A0/xx
Priority to IL15309101A priority patent/IL153091A0/xx
Priority to EP01940953A priority patent/EP1301202B1/fr
Priority to PCT/IL2001/000506 priority patent/WO2001091698A2/fr
Priority to AT01940953T priority patent/ATE494004T1/de
Priority to DE60143799T priority patent/DE60143799D1/de
Priority to AU74439/01A priority patent/AU7443901A/en
Priority to US10/297,060 priority patent/US7319143B2/en
Publication of IL136511A0 publication Critical patent/IL136511A0/xx
Priority to IL153091A priority patent/IL153091A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL13651100A 2000-06-01 2000-06-01 Genetically engineered mhc molecules IL136511A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL13651100A IL136511A0 (en) 2000-06-01 2000-06-01 Genetically engineered mhc molecules
IL15309101A IL153091A0 (en) 2000-06-01 2001-05-31 Genetically engineered mhc molecules
EP01940953A EP1301202B1 (fr) 2000-06-01 2001-05-31 Molecules du cmh genetiquement modifiees
PCT/IL2001/000506 WO2001091698A2 (fr) 2000-06-01 2001-05-31 Molecules du cmh genetiquement modifiees
AT01940953T ATE494004T1 (de) 2000-06-01 2001-05-31 Genetisch hergestellte mhc moleküle
DE60143799T DE60143799D1 (de) 2000-06-01 2001-05-31 Genetisch hergestellte mhc moleküle
AU74439/01A AU7443901A (en) 2000-06-01 2001-05-31 Genetically-engineered mhc molecules
US10/297,060 US7319143B2 (en) 2000-06-01 2001-05-31 Genetically-engineered MHC molecules
IL153091A IL153091A (en) 2000-06-01 2002-11-26 GENETICALLY ENGINEERED ??2-MICROGLOBULIN - CD3-?é MOLECULES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13651100A IL136511A0 (en) 2000-06-01 2000-06-01 Genetically engineered mhc molecules

Publications (1)

Publication Number Publication Date
IL136511A0 true IL136511A0 (en) 2001-06-14

Family

ID=11074209

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13651100A IL136511A0 (en) 2000-06-01 2000-06-01 Genetically engineered mhc molecules
IL153091A IL153091A (en) 2000-06-01 2002-11-26 GENETICALLY ENGINEERED ??2-MICROGLOBULIN - CD3-?é MOLECULES

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153091A IL153091A (en) 2000-06-01 2002-11-26 GENETICALLY ENGINEERED ??2-MICROGLOBULIN - CD3-?é MOLECULES

Country Status (7)

Country Link
US (1) US7319143B2 (fr)
EP (1) EP1301202B1 (fr)
AT (1) ATE494004T1 (fr)
AU (1) AU7443901A (fr)
DE (1) DE60143799D1 (fr)
IL (2) IL136511A0 (fr)
WO (1) WO2001091698A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101473A1 (fr) * 2002-05-30 2003-12-11 Sloan Kettering Institute For Cancer Research Tetrameres suicides contenant le cmh de classe 1 et leurs utilisations
EP1572929B1 (fr) * 2002-06-12 2011-05-11 Gavish-Galilee Bio Applications Ltd Beta2 microglobuline ancree sur membrane liee de facon covalente a des epitopes peptidiques du cmh de classe i
CA2595462A1 (fr) * 2005-01-21 2006-07-27 Nalan Utku Molecules de fusion hla et utilisations associees
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012127464A2 (fr) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Lymphocytes t constitutivement activés pour l'utilisation dans une thérapie cellulaire adoptive
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
LT2958943T (lt) 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
EP2970426B1 (fr) 2013-03-15 2019-08-28 Michael C. Milone Ciblage de cellules cytotoxiques par des récepteurs chimériques pour une immunothérapie adoptive
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA2931684C (fr) 2013-12-19 2024-02-20 Novartis Ag Recepteurs antigeniques chimeriques de la mesotheline humaine et leurs utilisations
EP3087101B1 (fr) 2013-12-20 2024-06-05 Novartis AG Récepteur d'antigène chimérique régulable
WO2015112626A1 (fr) 2014-01-21 2015-07-30 June Carl H Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP6736540B2 (ja) 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CN107567461A (zh) 2014-12-29 2018-01-09 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
WO2017015427A1 (fr) 2015-07-21 2017-01-26 Novartis Ag Méthodes pour améliorer l'efficacité et l'expansion de cellules immunitaires
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN116334205A (zh) 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
CN108699557B (zh) 2015-12-04 2025-08-15 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2018067992A1 (fr) 2016-10-07 2018-04-12 Novartis Ag Récepteurs antigéniques chimériques pour le traitement du cancer
KR20190130608A (ko) 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
EP3679065A4 (fr) * 2017-09-06 2021-05-19 California Institute of Technology Signalisation et récepteurs bifonctionnels présentant des antigènes (sabr)
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
CN111373031A (zh) 2017-11-10 2020-07-03 朱拉生物公司 基于主要组织相容性复合物的嵌合受体和其用于治疗自身免疫性疾病的用途
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019209631A1 (fr) * 2018-04-23 2019-10-31 Baylor College Of Medicine Récepteur chimère accessoire d'hla
CN112752767A (zh) * 2018-04-27 2021-05-04 克里斯珀医疗股份公司 细胞毒性t细胞耗竭的方法和组合物
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof
WO2020097188A1 (fr) * 2018-11-06 2020-05-14 Sangamo Therapeutics, Inc. Identification de molécules pour l'inhibition de la destruction de cellules à médiation par nk
EP4065158A2 (fr) 2019-11-26 2022-10-05 Novartis AG Récepteurs antigéniques chimériques et leurs utilisations
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
WO1997008328A1 (fr) * 1995-08-30 1997-03-06 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Elimination selective des lymphocites t reconnaissant des cibles specifiques preselectionnees
DE19545351C1 (de) 1995-12-05 1997-07-31 Univ Ludwigs Albert Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie

Also Published As

Publication number Publication date
ATE494004T1 (de) 2011-01-15
US20040137562A1 (en) 2004-07-15
EP1301202A4 (fr) 2005-01-05
US7319143B2 (en) 2008-01-15
EP1301202A2 (fr) 2003-04-16
IL153091A (en) 2011-01-31
WO2001091698A2 (fr) 2001-12-06
AU7443901A (en) 2001-12-11
EP1301202B1 (fr) 2011-01-05
WO2001091698A3 (fr) 2002-04-11
DE60143799D1 (de) 2011-02-17

Similar Documents

Publication Publication Date Title
ATE494004T1 (de) Genetisch hergestellte mhc moleküle
Cantoni et al. p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily
WO2002099119A3 (fr) Acides nucleiques et polypeptides associes a b7 utiles pour l'immunomodulation
WO2006023148A8 (fr) Lignees de cellules tueuses, naturelles, humaines et genetiquement modifiees
ATE228166T1 (de) Bifunktionelles protein, herstellung und verwendung
DK0726952T3 (da) Receptor benævnt ACT-4 på overfladen af aktiverede T-celler
CA2121798A1 (fr) Nouvelle cytokine
WO2001018035A3 (fr) Peptides derives de muc-1
AU2795292A (en) Synthetic dna sequence having enhanced insecticidal activity in maize
DE69841110D1 (de) Verlängerte cdns, die für sekretierte proteine kodieren
IL117425A0 (en) Receptor activation by gas6
ATE516348T1 (de) Glykoprotein vi und dessen anwendungen
CY1105364T1 (el) Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης
AU2002356601A1 (en) Bispecific anti-cd19 x anti-cd16 antibodies and uses thereof
WO1997026321A3 (fr) Expression recombinee de proteines a partir de lignees cellulaires secretoires
WO1998005684A3 (fr) Oligomeres peptidiques de liaison cmh et procedes d'utilisation
Tuomela et al. Eras of designer Tregs: Harnessing synthetic biology for immune suppression
EP3830274A2 (fr) Construction d'acide nucléique
Malarkannan The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions
DE69417223D1 (de) Ein menschlicher t-zell rezeptor der protein g-gekoppelte rezeptor familie
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
WO2003054019A3 (fr) Anticorps anti-tirc7 therapeutiques destines a etre utilises dans les maladies immunes ou autres
Krauthammer A special report on cloning.
WO2001055103A3 (fr) Recepteurs chimeriques du neuropeptide y